Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 148 | 2024 | 2763 | 8.090 |
Why?
|
Estrogen Receptor alpha | 42 | 2024 | 474 | 5.870 |
Why?
|
Receptors, Estrogen | 61 | 2024 | 828 | 4.140 |
Why?
|
Drug Resistance, Neoplasm | 30 | 2024 | 821 | 2.960 |
Why?
|
Tamoxifen | 29 | 2020 | 377 | 2.770 |
Why?
|
Mutation | 35 | 2024 | 6297 | 1.800 |
Why?
|
Molecular Targeted Therapy | 4 | 2021 | 407 | 1.660 |
Why?
|
Heat-Shock Proteins | 19 | 2005 | 202 | 1.640 |
Why?
|
Gene Expression Regulation, Neoplastic | 36 | 2020 | 2122 | 1.430 |
Why?
|
Antineoplastic Agents, Hormonal | 18 | 2019 | 271 | 1.310 |
Why?
|
Neoplasm Proteins | 15 | 2020 | 718 | 1.010 |
Why?
|
Neoplasm Metastasis | 8 | 2021 | 746 | 0.980 |
Why?
|
Receptors, Progesterone | 18 | 2012 | 897 | 0.950 |
Why?
|
Estrogens | 15 | 2020 | 522 | 0.910 |
Why?
|
Gene Expression Profiling | 12 | 2019 | 1910 | 0.820 |
Why?
|
Cell Line, Tumor | 38 | 2024 | 3751 | 0.810 |
Why?
|
Histone Deacetylases | 5 | 2014 | 122 | 0.790 |
Why?
|
Receptor, ErbB-2 | 11 | 2019 | 559 | 0.780 |
Why?
|
Receptors, Androgen | 5 | 2020 | 433 | 0.710 |
Why?
|
Tumor Cells, Cultured | 34 | 2009 | 1102 | 0.710 |
Why?
|
Transcription, Genetic | 19 | 2020 | 1757 | 0.690 |
Why?
|
Promoter Regions, Genetic | 16 | 2014 | 1418 | 0.690 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2020 | 142 | 0.660 |
Why?
|
Female | 117 | 2024 | 71684 | 0.640 |
Why?
|
Humans | 165 | 2024 | 133935 | 0.630 |
Why?
|
Precision Medicine | 3 | 2021 | 355 | 0.630 |
Why?
|
Antineoplastic Agents | 9 | 2018 | 1850 | 0.630 |
Why?
|
Estrogen Antagonists | 8 | 2011 | 106 | 0.630 |
Why?
|
Estrogen Receptor beta | 8 | 2017 | 87 | 0.620 |
Why?
|
Neoplasms, Hormone-Dependent | 11 | 2011 | 101 | 0.610 |
Why?
|
Gene Regulatory Networks | 1 | 2021 | 397 | 0.600 |
Why?
|
Repressor Proteins | 5 | 2014 | 869 | 0.580 |
Why?
|
Signal Transduction | 23 | 2024 | 4899 | 0.560 |
Why?
|
Estradiol | 11 | 2020 | 552 | 0.560 |
Why?
|
Transcriptional Activation | 15 | 2018 | 498 | 0.550 |
Why?
|
Sp1 Transcription Factor | 4 | 2012 | 45 | 0.540 |
Why?
|
Mammary Neoplasms, Experimental | 3 | 2009 | 246 | 0.540 |
Why?
|
RNA, Messenger | 23 | 2018 | 2902 | 0.520 |
Why?
|
Cell Proliferation | 17 | 2024 | 2539 | 0.510 |
Why?
|
DNA, Neoplasm | 18 | 2015 | 317 | 0.490 |
Why?
|
DNA-Binding Proteins | 12 | 2012 | 2161 | 0.470 |
Why?
|
Aromatase Inhibitors | 5 | 2020 | 79 | 0.470 |
Why?
|
Protein Kinase Inhibitors | 4 | 2024 | 611 | 0.460 |
Why?
|
ErbB Receptors | 2 | 2015 | 303 | 0.460 |
Why?
|
Triple Negative Breast Neoplasms | 4 | 2024 | 267 | 0.450 |
Why?
|
Biomarkers, Tumor | 10 | 2024 | 1720 | 0.440 |
Why?
|
Genes, p53 | 5 | 2007 | 234 | 0.440 |
Why?
|
Protein Isoforms | 10 | 2013 | 429 | 0.420 |
Why?
|
Neoplasms | 3 | 2021 | 3027 | 0.420 |
Why?
|
Oligonucleotide Array Sequence Analysis | 4 | 2009 | 1070 | 0.400 |
Why?
|
Progesterone | 4 | 2009 | 631 | 0.390 |
Why?
|
RNA, Neoplasm | 11 | 2013 | 144 | 0.390 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2018 | 1315 | 0.390 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 1353 | 0.380 |
Why?
|
Transfection | 14 | 2009 | 1089 | 0.380 |
Why?
|
Prognosis | 25 | 2019 | 5081 | 0.380 |
Why?
|
Protein Tyrosine Phosphatases | 2 | 2016 | 78 | 0.380 |
Why?
|
Cell Transformation, Neoplastic | 3 | 2014 | 644 | 0.370 |
Why?
|
Breast | 6 | 2016 | 218 | 0.370 |
Why?
|
Animals | 48 | 2024 | 36387 | 0.360 |
Why?
|
Polymerase Chain Reaction | 11 | 2012 | 1629 | 0.360 |
Why?
|
Serine | 3 | 2018 | 184 | 0.340 |
Why?
|
Mice, Nude | 13 | 2024 | 777 | 0.340 |
Why?
|
MCF-7 Cells | 10 | 2024 | 232 | 0.330 |
Why?
|
Phosphorylation | 13 | 2024 | 1701 | 0.330 |
Why?
|
Neoplasm Invasiveness | 8 | 2016 | 667 | 0.330 |
Why?
|
Mice | 30 | 2024 | 18909 | 0.330 |
Why?
|
Leptin | 3 | 2020 | 225 | 0.320 |
Why?
|
Exons | 11 | 2000 | 832 | 0.320 |
Why?
|
Xenograft Model Antitumor Assays | 7 | 2024 | 1006 | 0.320 |
Why?
|
Carcinoma, Ductal, Breast | 2 | 2009 | 91 | 0.310 |
Why?
|
Precancerous Conditions | 4 | 2001 | 288 | 0.310 |
Why?
|
Protein-Tyrosine Kinases | 3 | 2024 | 232 | 0.300 |
Why?
|
Quinazolines | 3 | 2017 | 184 | 0.300 |
Why?
|
Cell Movement | 8 | 2024 | 916 | 0.300 |
Why?
|
Proto-Oncogene Proteins c-yes | 2 | 2005 | 3 | 0.300 |
Why?
|
Genetic Variation | 5 | 2013 | 1621 | 0.290 |
Why?
|
Transcription Factors | 10 | 2024 | 2704 | 0.290 |
Why?
|
Protein Binding | 11 | 2020 | 1832 | 0.280 |
Why?
|
Nuclear Proteins | 5 | 2020 | 1334 | 0.280 |
Why?
|
Aromatase | 2 | 2020 | 26 | 0.280 |
Why?
|
Lymphatic Metastasis | 11 | 2009 | 453 | 0.280 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2009 | 295 | 0.270 |
Why?
|
Benzodioxoles | 1 | 2006 | 9 | 0.270 |
Why?
|
Drug Resistance | 15 | 1995 | 264 | 0.260 |
Why?
|
Genetic Markers | 3 | 2005 | 631 | 0.260 |
Why?
|
Base Sequence | 18 | 2013 | 3170 | 0.260 |
Why?
|
Immunohistochemistry | 10 | 2016 | 1761 | 0.260 |
Why?
|
MAP Kinase Signaling System | 3 | 2018 | 324 | 0.250 |
Why?
|
PTEN Phosphohydrolase | 2 | 2018 | 262 | 0.250 |
Why?
|
Heterogeneous-Nuclear Ribonucleoprotein D | 1 | 2005 | 5 | 0.250 |
Why?
|
Mammary Glands, Animal | 1 | 2009 | 477 | 0.250 |
Why?
|
Genetic Engineering | 1 | 2007 | 164 | 0.250 |
Why?
|
Disease-Free Survival | 5 | 2016 | 971 | 0.240 |
Why?
|
Gene Amplification | 9 | 2019 | 247 | 0.240 |
Why?
|
Antigens, Surface | 1 | 2005 | 119 | 0.240 |
Why?
|
RNA Stability | 1 | 2005 | 84 | 0.240 |
Why?
|
src-Family Kinases | 2 | 2006 | 97 | 0.240 |
Why?
|
Molecular Sequence Data | 17 | 2013 | 3967 | 0.230 |
Why?
|
3' Untranslated Regions | 1 | 2005 | 182 | 0.230 |
Why?
|
Down-Regulation | 7 | 2016 | 717 | 0.230 |
Why?
|
Apoptosis | 6 | 2024 | 1930 | 0.230 |
Why?
|
Cancer-Associated Fibroblasts | 1 | 2024 | 21 | 0.230 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2024 | 50 | 0.220 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2024 | 67 | 0.220 |
Why?
|
Bone Neoplasms | 3 | 2017 | 447 | 0.220 |
Why?
|
Doxorubicin | 4 | 2015 | 300 | 0.210 |
Why?
|
DNA | 9 | 2016 | 1674 | 0.210 |
Why?
|
BRCA1 Protein | 3 | 2009 | 82 | 0.210 |
Why?
|
Pyridines | 2 | 2024 | 247 | 0.210 |
Why?
|
Blotting, Western | 12 | 2010 | 1134 | 0.200 |
Why?
|
Ligands | 7 | 2009 | 572 | 0.200 |
Why?
|
Piperazines | 2 | 2024 | 257 | 0.200 |
Why?
|
Gene Expression | 7 | 2015 | 1614 | 0.200 |
Why?
|
Gene Expression Regulation | 5 | 2002 | 2656 | 0.200 |
Why?
|
Carcinoma | 2 | 2012 | 322 | 0.190 |
Why?
|
Mitochondria | 2 | 2021 | 746 | 0.190 |
Why?
|
CRISPR-Cas Systems | 1 | 2024 | 292 | 0.190 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2024 | 619 | 0.190 |
Why?
|
Nuclear Matrix-Associated Proteins | 2 | 2000 | 19 | 0.180 |
Why?
|
Matrix Attachment Region Binding Proteins | 2 | 2000 | 19 | 0.180 |
Why?
|
Cell Division | 10 | 2000 | 774 | 0.180 |
Why?
|
Response Elements | 3 | 2012 | 106 | 0.180 |
Why?
|
RNA-Binding Proteins | 1 | 2005 | 609 | 0.180 |
Why?
|
Cloning, Molecular | 6 | 1997 | 911 | 0.180 |
Why?
|
Carcinoma, Lobular | 1 | 2001 | 26 | 0.180 |
Why?
|
DNA Primers | 7 | 2007 | 669 | 0.180 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 8 | 2011 | 1326 | 0.180 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2019 | 82 | 0.180 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2001 | 141 | 0.170 |
Why?
|
Binding Sites | 4 | 2009 | 1370 | 0.170 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2001 | 74 | 0.170 |
Why?
|
RNA | 2 | 1996 | 600 | 0.170 |
Why?
|
Macrophage Activation | 1 | 2020 | 68 | 0.170 |
Why?
|
Up-Regulation | 3 | 2012 | 905 | 0.170 |
Why?
|
Protein-Arginine N-Methyltransferases | 1 | 2020 | 45 | 0.160 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2001 | 259 | 0.160 |
Why?
|
Proportional Hazards Models | 5 | 2014 | 1484 | 0.160 |
Why?
|
Osteolysis | 1 | 1999 | 10 | 0.160 |
Why?
|
Phenotype | 13 | 2011 | 4548 | 0.160 |
Why?
|
Liquid Biopsy | 1 | 2019 | 16 | 0.160 |
Why?
|
DNA Topoisomerases, Type II | 1 | 1999 | 25 | 0.160 |
Why?
|
Acetylation | 5 | 2009 | 183 | 0.160 |
Why?
|
Receptors, G-Protein-Coupled | 2 | 2014 | 315 | 0.160 |
Why?
|
Transcriptome | 4 | 2014 | 1127 | 0.160 |
Why?
|
HeLa Cells | 4 | 2009 | 828 | 0.160 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2009 | 1735 | 0.160 |
Why?
|
RNA Splicing | 6 | 2013 | 250 | 0.150 |
Why?
|
Gene Deletion | 4 | 2002 | 809 | 0.150 |
Why?
|
Lysine | 3 | 2009 | 205 | 0.150 |
Why?
|
Neoplastic Stem Cells | 2 | 2018 | 352 | 0.150 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2020 | 217 | 0.150 |
Why?
|
Genes, Tumor Suppressor | 1 | 1999 | 225 | 0.150 |
Why?
|
Receptor, Notch4 | 1 | 2018 | 5 | 0.150 |
Why?
|
rho Guanine Nucleotide Dissociation Inhibitor alpha | 2 | 2015 | 10 | 0.150 |
Why?
|
Protein Array Analysis | 2 | 2016 | 107 | 0.150 |
Why?
|
HSP27 Heat-Shock Proteins | 3 | 2005 | 8 | 0.140 |
Why?
|
Mitogen-Activated Protein Kinases | 4 | 2012 | 212 | 0.140 |
Why?
|
Quercetin | 1 | 1997 | 11 | 0.140 |
Why?
|
Nuclear Matrix | 1 | 1997 | 21 | 0.140 |
Why?
|
Receptor, Notch1 | 1 | 2018 | 79 | 0.140 |
Why?
|
Cell Survival | 2 | 2018 | 889 | 0.140 |
Why?
|
Time Factors | 5 | 2011 | 6590 | 0.140 |
Why?
|
Nuclear Receptor Co-Repressor 1 | 3 | 2013 | 55 | 0.140 |
Why?
|
Estrogen Receptor Modulators | 3 | 2003 | 39 | 0.140 |
Why?
|
Receptors, Somatomedin | 2 | 2016 | 24 | 0.130 |
Why?
|
Receptor, IGF Type 1 | 4 | 2024 | 95 | 0.130 |
Why?
|
Bone Development | 1 | 2017 | 60 | 0.130 |
Why?
|
Bone Remodeling | 1 | 2017 | 61 | 0.130 |
Why?
|
Molecular Chaperones | 3 | 2005 | 173 | 0.130 |
Why?
|
Subtraction Technique | 1 | 1996 | 36 | 0.130 |
Why?
|
Frozen Sections | 1 | 1996 | 31 | 0.130 |
Why?
|
Mitogen-Activated Protein Kinase Phosphatases | 1 | 2016 | 15 | 0.130 |
Why?
|
Selective Estrogen Receptor Modulators | 3 | 2012 | 62 | 0.130 |
Why?
|
Histone Deacetylase 1 | 3 | 2013 | 22 | 0.130 |
Why?
|
Dual-Specificity Phosphatases | 1 | 2016 | 24 | 0.130 |
Why?
|
Immunoblotting | 3 | 2011 | 317 | 0.130 |
Why?
|
Electrophoretic Mobility Shift Assay | 3 | 2011 | 53 | 0.130 |
Why?
|
Membrane Glycoproteins | 6 | 2002 | 432 | 0.130 |
Why?
|
Plasmids | 4 | 2011 | 527 | 0.130 |
Why?
|
HSP90 Heat-Shock Proteins | 2 | 2013 | 38 | 0.120 |
Why?
|
Receptors, CXCR4 | 2 | 2020 | 71 | 0.120 |
Why?
|
Drug Design | 1 | 2016 | 168 | 0.120 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2016 | 109 | 0.120 |
Why?
|
Thyroid Hormone Receptors beta | 1 | 2015 | 21 | 0.120 |
Why?
|
Mi-2 Nucleosome Remodeling and Deacetylase Complex | 1 | 2014 | 15 | 0.120 |
Why?
|
DNA, Complementary | 4 | 2001 | 472 | 0.120 |
Why?
|
Disease Progression | 5 | 2014 | 2242 | 0.110 |
Why?
|
Recombinant Fusion Proteins | 4 | 2009 | 801 | 0.110 |
Why?
|
Patient Care Planning | 2 | 2005 | 133 | 0.110 |
Why?
|
Cytoskeleton | 1 | 2014 | 175 | 0.110 |
Why?
|
Trastuzumab | 3 | 2019 | 154 | 0.110 |
Why?
|
Multivariate Analysis | 4 | 2007 | 1489 | 0.110 |
Why?
|
Mutagenesis | 1 | 1994 | 354 | 0.100 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2019 | 351 | 0.100 |
Why?
|
Oncogene Protein v-akt | 2 | 2011 | 33 | 0.100 |
Why?
|
Catechin | 1 | 2013 | 14 | 0.100 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2011 | 792 | 0.100 |
Why?
|
Patient Selection | 1 | 2016 | 734 | 0.100 |
Why?
|
RNA Precursors | 1 | 2013 | 65 | 0.100 |
Why?
|
Nucleic Acid Hybridization | 3 | 2005 | 397 | 0.100 |
Why?
|
Middle Aged | 14 | 2017 | 29409 | 0.100 |
Why?
|
Sin3 Histone Deacetylase and Corepressor Complex | 1 | 2011 | 5 | 0.090 |
Why?
|
Hyperplasia | 3 | 2001 | 203 | 0.090 |
Why?
|
Cell Adhesion | 2 | 2006 | 363 | 0.090 |
Why?
|
Endothelin-1 | 1 | 2011 | 45 | 0.090 |
Why?
|
CCAAT-Binding Factor | 1 | 2011 | 6 | 0.090 |
Why?
|
Adenocarcinoma | 4 | 2000 | 1070 | 0.090 |
Why?
|
Guanine Nucleotide Dissociation Inhibitors | 1 | 2011 | 12 | 0.090 |
Why?
|
Stilbenes | 1 | 2011 | 42 | 0.090 |
Why?
|
Lactoferrin | 1 | 2011 | 78 | 0.090 |
Why?
|
Transcription Factor AP-1 | 3 | 2014 | 111 | 0.090 |
Why?
|
Amino Acid Substitution | 2 | 2009 | 412 | 0.090 |
Why?
|
Cell Line | 8 | 2010 | 2836 | 0.090 |
Why?
|
Ribonuclease III | 1 | 2011 | 103 | 0.090 |
Why?
|
Genes, Reporter | 3 | 2009 | 395 | 0.090 |
Why?
|
STAT3 Transcription Factor | 1 | 2012 | 230 | 0.090 |
Why?
|
Cyclin D1 | 3 | 2011 | 123 | 0.090 |
Why?
|
DEAD-box RNA Helicases | 1 | 2011 | 147 | 0.080 |
Why?
|
Mice, Inbred BALB C | 3 | 2006 | 1079 | 0.080 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2011 | 197 | 0.080 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 1990 | 73 | 0.080 |
Why?
|
Transcription Factor TFIIB | 1 | 2009 | 10 | 0.080 |
Why?
|
Trefoil Factor-1 | 1 | 2009 | 7 | 0.080 |
Why?
|
Radioligand Assay | 1 | 2009 | 27 | 0.080 |
Why?
|
Neoadjuvant Therapy | 3 | 2019 | 404 | 0.080 |
Why?
|
TATA-Box Binding Protein | 1 | 2009 | 31 | 0.080 |
Why?
|
Transforming Growth Factor alpha | 1 | 2009 | 28 | 0.080 |
Why?
|
Sequence Deletion | 4 | 1996 | 537 | 0.080 |
Why?
|
Co-Repressor Proteins | 1 | 2009 | 39 | 0.080 |
Why?
|
DNA Methylation | 1 | 2016 | 1143 | 0.080 |
Why?
|
Point Mutation | 4 | 2002 | 360 | 0.080 |
Why?
|
Genes, BRCA1 | 1 | 2009 | 61 | 0.080 |
Why?
|
Nuclear Receptor Coactivator 3 | 2 | 2009 | 351 | 0.080 |
Why?
|
Neuregulin-1 | 1 | 2009 | 13 | 0.080 |
Why?
|
Mammary Tumor Virus, Mouse | 1 | 2009 | 107 | 0.080 |
Why?
|
Ovariectomy | 1 | 2009 | 188 | 0.080 |
Why?
|
Tretinoin | 1 | 2009 | 118 | 0.080 |
Why?
|
Genes, Neoplasm | 1 | 2009 | 90 | 0.080 |
Why?
|
Thiazolidinediones | 1 | 2009 | 85 | 0.080 |
Why?
|
Tumor Burden | 1 | 2009 | 257 | 0.080 |
Why?
|
Models, Biological | 3 | 2009 | 1532 | 0.080 |
Why?
|
Cricetinae | 5 | 2009 | 398 | 0.070 |
Why?
|
Genes, Dominant | 2 | 2004 | 254 | 0.070 |
Why?
|
Adult | 10 | 2017 | 31950 | 0.070 |
Why?
|
Cell Nucleus | 2 | 2001 | 688 | 0.070 |
Why?
|
Models, Genetic | 3 | 2016 | 789 | 0.070 |
Why?
|
Genome-Wide Association Study | 3 | 2013 | 1871 | 0.070 |
Why?
|
Pharmacogenetics | 1 | 2009 | 196 | 0.070 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2011 | 392 | 0.070 |
Why?
|
Nuclear Receptor Coactivator 2 | 1 | 2009 | 211 | 0.070 |
Why?
|
Luciferases | 2 | 2005 | 137 | 0.070 |
Why?
|
Chromatin Immunoprecipitation | 3 | 2013 | 248 | 0.070 |
Why?
|
Protein Processing, Post-Translational | 1 | 2009 | 382 | 0.070 |
Why?
|
Transplantation, Heterologous | 4 | 2011 | 275 | 0.070 |
Why?
|
Risk | 1 | 2009 | 832 | 0.070 |
Why?
|
Gene Knockdown Techniques | 3 | 2015 | 395 | 0.070 |
Why?
|
Cell Growth Processes | 1 | 2006 | 69 | 0.070 |
Why?
|
Neoplasm Transplantation | 3 | 2016 | 399 | 0.070 |
Why?
|
Proteins | 3 | 1999 | 1087 | 0.070 |
Why?
|
Dual Specificity Phosphatase 6 | 1 | 2006 | 2 | 0.070 |
Why?
|
Tumor Microenvironment | 2 | 2024 | 690 | 0.060 |
Why?
|
Tumor Suppressor Proteins | 1 | 2009 | 510 | 0.060 |
Why?
|
Drug Synergism | 1 | 2006 | 239 | 0.060 |
Why?
|
Genetic Predisposition to Disease | 2 | 2009 | 3475 | 0.060 |
Why?
|
ELAV-Like Protein 1 | 1 | 2005 | 8 | 0.060 |
Why?
|
ELAV Proteins | 1 | 2005 | 14 | 0.060 |
Why?
|
Uridine | 1 | 2005 | 36 | 0.060 |
Why?
|
HSP70 Heat-Shock Proteins | 2 | 1997 | 73 | 0.060 |
Why?
|
Fibroblasts | 2 | 2024 | 922 | 0.060 |
Why?
|
Structure-Activity Relationship | 3 | 2000 | 611 | 0.060 |
Why?
|
Trans-Activators | 3 | 2005 | 830 | 0.060 |
Why?
|
Adenine | 1 | 2005 | 122 | 0.060 |
Why?
|
Glycoproteins | 1 | 1987 | 379 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-akt | 3 | 2014 | 508 | 0.060 |
Why?
|
Upstream Stimulatory Factors | 1 | 2004 | 9 | 0.060 |
Why?
|
Leucine Zippers | 1 | 2004 | 17 | 0.060 |
Why?
|
Helix-Loop-Helix Motifs | 1 | 2004 | 43 | 0.060 |
Why?
|
Predictive Value of Tests | 3 | 2005 | 2295 | 0.060 |
Why?
|
Dihydrotestosterone | 2 | 2020 | 71 | 0.060 |
Why?
|
NIH 3T3 Cells | 1 | 2004 | 96 | 0.060 |
Why?
|
Glutathione Transferase | 3 | 2001 | 163 | 0.050 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 1 | 2004 | 170 | 0.050 |
Why?
|
Proto-Oncogene Proteins | 3 | 2011 | 616 | 0.050 |
Why?
|
HLA-B Antigens | 1 | 2024 | 31 | 0.050 |
Why?
|
Antigen Presentation | 1 | 2024 | 117 | 0.050 |
Why?
|
Regulatory Sequences, Nucleic Acid | 2 | 2012 | 170 | 0.050 |
Why?
|
Mice, Transgenic | 1 | 2009 | 2526 | 0.050 |
Why?
|
Blotting, Southern | 6 | 1997 | 222 | 0.050 |
Why?
|
Stromal Cells | 2 | 2017 | 313 | 0.050 |
Why?
|
Aged | 9 | 2017 | 21745 | 0.050 |
Why?
|
Heat-Shock Response | 1 | 2003 | 35 | 0.050 |
Why?
|
Sp3 Transcription Factor | 1 | 2002 | 7 | 0.050 |
Why?
|
Histone Acetyltransferases | 2 | 2020 | 317 | 0.050 |
Why?
|
Loss of Heterozygosity | 2 | 2001 | 135 | 0.050 |
Why?
|
SUMO-1 Protein | 1 | 2002 | 8 | 0.050 |
Why?
|
MAP Kinase Kinase Kinase 1 | 1 | 2002 | 15 | 0.050 |
Why?
|
Cathepsin D | 2 | 2010 | 17 | 0.050 |
Why?
|
Rats | 1 | 2009 | 3883 | 0.050 |
Why?
|
Nitriles | 2 | 2014 | 155 | 0.050 |
Why?
|
Homeodomain Proteins | 1 | 2005 | 584 | 0.050 |
Why?
|
RNA Polymerase II | 2 | 2013 | 102 | 0.050 |
Why?
|
Triazoles | 2 | 2014 | 142 | 0.050 |
Why?
|
Interdisciplinary Communication | 1 | 2003 | 134 | 0.050 |
Why?
|
Chromatin | 2 | 2005 | 609 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-fos | 2 | 2014 | 59 | 0.050 |
Why?
|
Hematopoietic Stem Cells | 1 | 2006 | 563 | 0.050 |
Why?
|
Cell Differentiation | 1 | 2009 | 2025 | 0.050 |
Why?
|
Peptides | 2 | 2024 | 859 | 0.050 |
Why?
|
Enzyme Activation | 2 | 2014 | 644 | 0.050 |
Why?
|
Chromosomes, Human, Pair 3 | 2 | 1994 | 100 | 0.050 |
Why?
|
Fatty Acids | 1 | 2024 | 370 | 0.050 |
Why?
|
Epidermal Growth Factor | 2 | 2012 | 125 | 0.040 |
Why?
|
Proto-Oncogenes | 2 | 1991 | 34 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 2 | 2011 | 97 | 0.040 |
Why?
|
Antibodies, Monoclonal | 3 | 2000 | 1069 | 0.040 |
Why?
|
Polymorphism, Restriction Fragment Length | 2 | 1991 | 153 | 0.040 |
Why?
|
Genes | 2 | 1992 | 450 | 0.040 |
Why?
|
Immunoprecipitation | 2 | 2011 | 204 | 0.040 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2024 | 501 | 0.040 |
Why?
|
Osteosarcoma | 2 | 2000 | 263 | 0.040 |
Why?
|
Molecular Conformation | 1 | 2020 | 110 | 0.040 |
Why?
|
COS Cells | 3 | 2010 | 283 | 0.040 |
Why?
|
Pregnancy | 2 | 2009 | 7522 | 0.040 |
Why?
|
Insulin-Like Growth Factor I | 3 | 2012 | 352 | 0.040 |
Why?
|
Macromolecular Substances | 2 | 2000 | 183 | 0.040 |
Why?
|
Parathyroid Hormone-Related Protein | 1 | 1999 | 9 | 0.040 |
Why?
|
Sequence Analysis, RNA | 2 | 2013 | 428 | 0.040 |
Why?
|
Genes, Retinoblastoma | 1 | 1999 | 21 | 0.040 |
Why?
|
Sensitivity and Specificity | 1 | 2005 | 2163 | 0.040 |
Why?
|
Topoisomerase II Inhibitors | 1 | 1999 | 15 | 0.040 |
Why?
|
Treatment Outcome | 2 | 2007 | 13010 | 0.040 |
Why?
|
Gonadal Steroid Hormones | 1 | 2020 | 98 | 0.040 |
Why?
|
DNA Fragmentation | 1 | 1999 | 61 | 0.040 |
Why?
|
Survival Analysis | 4 | 2016 | 1596 | 0.040 |
Why?
|
Molecular Probe Techniques | 1 | 1999 | 23 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-jun | 2 | 2014 | 37 | 0.040 |
Why?
|
Somatomedins | 2 | 1989 | 37 | 0.040 |
Why?
|
Chromosomes, Human, Pair 14 | 1 | 1999 | 102 | 0.040 |
Why?
|
Amino Acid Sequence | 5 | 2001 | 2781 | 0.040 |
Why?
|
Clone Cells | 1 | 1999 | 180 | 0.040 |
Why?
|
Isoenzymes | 1 | 1999 | 231 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 1999 | 183 | 0.040 |
Why?
|
Melanoma | 2 | 1998 | 974 | 0.040 |
Why?
|
Remission Induction | 1 | 2019 | 308 | 0.040 |
Why?
|
Mice, Knockout | 1 | 2007 | 3981 | 0.040 |
Why?
|
Rhabdomyosarcoma | 1 | 2001 | 209 | 0.040 |
Why?
|
Spheroids, Cellular | 1 | 2018 | 63 | 0.040 |
Why?
|
RNA, Small Interfering | 2 | 2011 | 714 | 0.040 |
Why?
|
Actins | 2 | 1990 | 351 | 0.040 |
Why?
|
Heat Shock Transcription Factors | 1 | 1997 | 20 | 0.040 |
Why?
|
NF-kappa B | 2 | 2011 | 482 | 0.040 |
Why?
|
Polymorphism, Genetic | 3 | 1993 | 896 | 0.040 |
Why?
|
Drosophila | 1 | 2002 | 824 | 0.040 |
Why?
|
In Situ Hybridization | 2 | 1995 | 484 | 0.030 |
Why?
|
Autocrine Communication | 1 | 1997 | 29 | 0.030 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2019 | 791 | 0.030 |
Why?
|
Polymorphism, Single-Stranded Conformational | 1 | 1997 | 73 | 0.030 |
Why?
|
Hydroxyurea | 1 | 1998 | 86 | 0.030 |
Why?
|
Protein Domains | 1 | 2018 | 252 | 0.030 |
Why?
|
Pilot Projects | 2 | 1999 | 1484 | 0.030 |
Why?
|
Superoxide Dismutase | 2 | 2012 | 187 | 0.030 |
Why?
|
Osteoclasts | 1 | 2017 | 74 | 0.030 |
Why?
|
Air | 1 | 1996 | 26 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 1999 | 407 | 0.030 |
Why?
|
Single-Cell Analysis | 1 | 2020 | 348 | 0.030 |
Why?
|
Desiccation | 1 | 1996 | 46 | 0.030 |
Why?
|
Two-Hybrid System Techniques | 2 | 2010 | 67 | 0.030 |
Why?
|
Tissue Fixation | 1 | 1996 | 41 | 0.030 |
Why?
|
Transcription Factor AP-2 | 1 | 1996 | 23 | 0.030 |
Why?
|
DNA Transposable Elements | 1 | 1997 | 188 | 0.030 |
Why?
|
Cervix Uteri | 1 | 1996 | 64 | 0.030 |
Why?
|
Translocation, Genetic | 1 | 2018 | 362 | 0.030 |
Why?
|
Osteoblasts | 1 | 2017 | 164 | 0.030 |
Why?
|
Macrophages | 1 | 2020 | 704 | 0.030 |
Why?
|
Oxidative Stress | 1 | 2000 | 870 | 0.030 |
Why?
|
Protein Multimerization | 1 | 1996 | 143 | 0.030 |
Why?
|
Taxoids | 1 | 2015 | 72 | 0.030 |
Why?
|
S Phase | 1 | 1995 | 78 | 0.030 |
Why?
|
Chromosome Deletion | 1 | 1998 | 664 | 0.030 |
Why?
|
Estrogen Receptor Antagonists | 1 | 2014 | 4 | 0.030 |
Why?
|
Androstenedione | 1 | 2014 | 12 | 0.030 |
Why?
|
Chromosome Aberrations | 2 | 1995 | 626 | 0.030 |
Why?
|
Alternative Splicing | 1 | 1996 | 375 | 0.030 |
Why?
|
Proteomics | 1 | 2018 | 592 | 0.030 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 1994 | 111 | 0.030 |
Why?
|
Prostatic Hyperplasia | 1 | 1994 | 118 | 0.030 |
Why?
|
Lymph Nodes | 1 | 1995 | 397 | 0.030 |
Why?
|
Hot Temperature | 1 | 1994 | 145 | 0.030 |
Why?
|
Male | 5 | 2011 | 65904 | 0.030 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2017 | 554 | 0.030 |
Why?
|
Tea | 1 | 2013 | 19 | 0.030 |
Why?
|
Regression Analysis | 1 | 1995 | 832 | 0.030 |
Why?
|
Antibodies | 1 | 1994 | 382 | 0.020 |
Why?
|
Endometrial Neoplasms | 1 | 1994 | 114 | 0.020 |
Why?
|
Small Ubiquitin-Related Modifier Proteins | 1 | 2012 | 20 | 0.020 |
Why?
|
Cyclin-Dependent Kinase 2 | 1 | 2012 | 52 | 0.020 |
Why?
|
Cells, Cultured | 2 | 1997 | 3167 | 0.020 |
Why?
|
Sumoylation | 1 | 2012 | 38 | 0.020 |
Why?
|
Recombinant Proteins | 2 | 1998 | 1438 | 0.020 |
Why?
|
Receptors, Leptin | 1 | 2012 | 42 | 0.020 |
Why?
|
Receptor, Endothelin A | 1 | 2011 | 13 | 0.020 |
Why?
|
Cyclic AMP Response Element-Binding Protein | 1 | 2012 | 109 | 0.020 |
Why?
|
Endothelin A Receptor Antagonists | 1 | 2011 | 8 | 0.020 |
Why?
|
Oligodeoxyribonucleotides | 1 | 1992 | 139 | 0.020 |
Why?
|
Deoxyribonuclease HindIII | 1 | 1991 | 5 | 0.020 |
Why?
|
Deoxyribonucleases, Type II Site-Specific | 1 | 1991 | 50 | 0.020 |
Why?
|
Bone and Bones | 1 | 1994 | 310 | 0.020 |
Why?
|
Breast Neoplasms, Male | 1 | 2011 | 16 | 0.020 |
Why?
|
Casein Kinase II | 1 | 2011 | 15 | 0.020 |
Why?
|
Caco-2 Cells | 1 | 2011 | 97 | 0.020 |
Why?
|
Incidence | 1 | 1999 | 3402 | 0.020 |
Why?
|
rho-Specific Guanine Nucleotide Dissociation Inhibitors | 1 | 2011 | 8 | 0.020 |
Why?
|
RNA Processing, Post-Transcriptional | 1 | 2011 | 75 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2014 | 1139 | 0.020 |
Why?
|
Chenodeoxycholic Acid | 1 | 2011 | 14 | 0.020 |
Why?
|
Tumor Stem Cell Assay | 1 | 2011 | 37 | 0.020 |
Why?
|
Ki-67 Antigen | 1 | 2011 | 119 | 0.020 |
Why?
|
Isoxazoles | 1 | 2011 | 24 | 0.020 |
Why?
|
Genetic Testing | 1 | 2018 | 1094 | 0.020 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 129 | 0.020 |
Why?
|
Lipid Metabolism | 1 | 1994 | 383 | 0.020 |
Why?
|
Retrospective Studies | 2 | 2011 | 17487 | 0.020 |
Why?
|
Gene Frequency | 1 | 2013 | 778 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 1995 | 1386 | 0.020 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2011 | 110 | 0.020 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2013 | 542 | 0.020 |
Why?
|
rho GTP-Binding Proteins | 1 | 2011 | 70 | 0.020 |
Why?
|
Chromosome Mapping | 2 | 1994 | 1123 | 0.020 |
Why?
|
Alleles | 2 | 2013 | 1705 | 0.020 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2011 | 271 | 0.020 |
Why?
|
RNA Interference | 1 | 2012 | 544 | 0.020 |
Why?
|
Gene Silencing | 1 | 2011 | 247 | 0.020 |
Why?
|
Random Allocation | 1 | 2011 | 450 | 0.020 |
Why?
|
Receptor Cross-Talk | 1 | 2010 | 37 | 0.020 |
Why?
|
Insulin Receptor Substrate Proteins | 1 | 2010 | 80 | 0.020 |
Why?
|
Insulin-Like Growth Factor II | 1 | 1989 | 45 | 0.020 |
Why?
|
Retinoid X Receptors | 1 | 2009 | 32 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2010 | 115 | 0.020 |
Why?
|
p300-CBP Transcription Factors | 1 | 2009 | 51 | 0.020 |
Why?
|
Follow-Up Studies | 1 | 2019 | 5511 | 0.020 |
Why?
|
Secondary Prevention | 1 | 2011 | 225 | 0.020 |
Why?
|
Cricetulus | 1 | 2009 | 96 | 0.020 |
Why?
|
Mice, SCID | 1 | 2010 | 613 | 0.020 |
Why?
|
Tyrosine | 1 | 2009 | 158 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2012 | 525 | 0.020 |
Why?
|
CHO Cells | 1 | 2009 | 166 | 0.020 |
Why?
|
PPAR gamma | 1 | 2009 | 86 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 1994 | 1153 | 0.020 |
Why?
|
Chromatography, Liquid | 1 | 2010 | 230 | 0.020 |
Why?
|
Blood Proteins | 1 | 1989 | 136 | 0.020 |
Why?
|
Ubiquitination | 1 | 2009 | 183 | 0.020 |
Why?
|
Cell Cycle | 1 | 2011 | 626 | 0.020 |
Why?
|
Protein Structure, Tertiary | 2 | 2001 | 781 | 0.020 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 1989 | 114 | 0.020 |
Why?
|
Transforming Growth Factors | 1 | 1988 | 21 | 0.020 |
Why?
|
Microscopy, Confocal | 1 | 2010 | 371 | 0.020 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2009 | 327 | 0.020 |
Why?
|
Multigene Family | 1 | 1989 | 323 | 0.020 |
Why?
|
X Chromosome | 1 | 1989 | 342 | 0.020 |
Why?
|
Odds Ratio | 1 | 2011 | 1337 | 0.020 |
Why?
|
Tandem Mass Spectrometry | 1 | 2010 | 279 | 0.020 |
Why?
|
Computational Biology | 1 | 2013 | 887 | 0.020 |
Why?
|
Receptors, Cell Surface | 1 | 1989 | 494 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2013 | 960 | 0.020 |
Why?
|
Placenta | 1 | 1991 | 535 | 0.020 |
Why?
|
Sequence Homology, Amino Acid | 2 | 2001 | 673 | 0.020 |
Why?
|
Carcinoma in Situ | 2 | 2001 | 73 | 0.020 |
Why?
|
Arginine | 1 | 2009 | 349 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 1993 | 1833 | 0.020 |
Why?
|
Genotype | 1 | 2013 | 2807 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 1997 | 1788 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2011 | 4777 | 0.020 |
Why?
|
LIM Domain Proteins | 1 | 2005 | 62 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2009 | 941 | 0.010 |
Why?
|
Mutation, Missense | 1 | 2009 | 930 | 0.010 |
Why?
|
Genomics | 1 | 2013 | 1675 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2013 | 2940 | 0.010 |
Why?
|
Genes, erbB-2 | 1 | 2003 | 38 | 0.010 |
Why?
|
Mice, Inbred C57BL | 2 | 2006 | 4822 | 0.010 |
Why?
|
Cytoprotection | 1 | 2003 | 39 | 0.010 |
Why?
|
Acetyltransferases | 1 | 2003 | 91 | 0.010 |
Why?
|
Phytotherapy | 1 | 2003 | 53 | 0.010 |
Why?
|
Hydrolysis | 1 | 2003 | 164 | 0.010 |
Why?
|
TNF-Related Apoptosis-Inducing Ligand | 1 | 2002 | 25 | 0.010 |
Why?
|
Protease Inhibitors | 1 | 2003 | 100 | 0.010 |
Why?
|
Oncogene Proteins | 1 | 2003 | 151 | 0.010 |
Why?
|
Hydroxamic Acids | 1 | 2002 | 65 | 0.010 |
Why?
|
Smad3 Protein | 1 | 2002 | 59 | 0.010 |
Why?
|
Amino Acid Motifs | 1 | 2002 | 204 | 0.010 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2003 | 401 | 0.010 |
Why?
|
Growth Substances | 1 | 2001 | 115 | 0.010 |
Why?
|
Receptors, Steroid | 1 | 2003 | 276 | 0.010 |
Why?
|
Analysis of Variance | 2 | 1994 | 1046 | 0.010 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2002 | 168 | 0.010 |
Why?
|
Research | 1 | 2003 | 272 | 0.010 |
Why?
|
Chloramphenicol O-Acetyltransferase | 1 | 2000 | 80 | 0.010 |
Why?
|
Recurrence | 2 | 1996 | 1471 | 0.010 |
Why?
|
Forkhead Box Protein O1 | 1 | 2001 | 95 | 0.010 |
Why?
|
Hybridomas | 1 | 2000 | 41 | 0.010 |
Why?
|
Pentose Phosphate Pathway | 1 | 2000 | 44 | 0.010 |
Why?
|
G1 Phase | 1 | 2001 | 67 | 0.010 |
Why?
|
In Vitro Techniques | 1 | 2002 | 991 | 0.010 |
Why?
|
Lipid Peroxidation | 1 | 2000 | 99 | 0.010 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 1 | 2000 | 94 | 0.010 |
Why?
|
Tissue Distribution | 1 | 2001 | 400 | 0.010 |
Why?
|
Gene Library | 1 | 2001 | 225 | 0.010 |
Why?
|
Antibody Specificity | 1 | 2000 | 206 | 0.010 |
Why?
|
Depression, Chemical | 1 | 2000 | 43 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 2009 | 1623 | 0.010 |
Why?
|
Cross Reactions | 1 | 2000 | 195 | 0.010 |
Why?
|
Mitotic Index | 1 | 1999 | 18 | 0.010 |
Why?
|
Transduction, Genetic | 1 | 2000 | 296 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2006 | 3056 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2002 | 708 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2003 | 1315 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2002 | 607 | 0.010 |
Why?
|
Forkhead Transcription Factors | 1 | 2001 | 381 | 0.010 |
Why?
|
Heat Stress Disorders | 1 | 1998 | 10 | 0.010 |
Why?
|
Survival Rate | 2 | 1994 | 2210 | 0.010 |
Why?
|
Breast Diseases | 1 | 1998 | 38 | 0.010 |
Why?
|
Neoplasms, Multiple Primary | 1 | 1998 | 72 | 0.010 |
Why?
|
Aged, 80 and over | 3 | 1996 | 7211 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 2000 | 823 | 0.010 |
Why?
|
Cytokines | 1 | 2003 | 1396 | 0.010 |
Why?
|
Metaphase | 1 | 1995 | 35 | 0.010 |
Why?
|
Heterozygote | 1 | 1998 | 718 | 0.010 |
Why?
|
Ribonucleases | 1 | 1995 | 51 | 0.010 |
Why?
|
GRB7 Adaptor Protein | 1 | 1994 | 2 | 0.010 |
Why?
|
3T3 Cells | 1 | 1994 | 123 | 0.010 |
Why?
|
Gene Dosage | 1 | 1995 | 456 | 0.010 |
Why?
|
Biopsy | 1 | 1997 | 1304 | 0.010 |
Why?
|
Axilla | 1 | 1993 | 43 | 0.010 |
Why?
|
Codon | 1 | 1993 | 108 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 1995 | 621 | 0.010 |
Why?
|
DNA, Single-Stranded | 1 | 1993 | 78 | 0.010 |
Why?
|
Genome | 1 | 1995 | 526 | 0.010 |
Why?
|
Nucleic Acid Conformation | 1 | 1993 | 198 | 0.010 |
Why?
|
Caenorhabditis elegans | 1 | 1994 | 245 | 0.010 |
Why?
|
Postmenopause | 1 | 1993 | 157 | 0.010 |
Why?
|
Frameshift Mutation | 1 | 1993 | 199 | 0.010 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2000 | 1000 | 0.010 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 1993 | 374 | 0.010 |
Why?
|
Immune Sera | 1 | 1990 | 95 | 0.010 |
Why?
|
Cell Aggregation | 1 | 1990 | 25 | 0.010 |
Why?
|
Culture Techniques | 1 | 1990 | 82 | 0.010 |
Why?
|
Colchicine | 1 | 1990 | 39 | 0.010 |
Why?
|
Vinblastine | 1 | 1990 | 58 | 0.010 |
Why?
|
Menopause | 1 | 1990 | 88 | 0.010 |
Why?
|
Methylation | 1 | 1990 | 231 | 0.010 |
Why?
|
Binding, Competitive | 1 | 1989 | 194 | 0.010 |
Why?
|
Electrophoresis | 1 | 1989 | 52 | 0.010 |
Why?
|
Blotting, Northern | 1 | 1989 | 270 | 0.000 |
Why?
|
Hybrid Cells | 1 | 1989 | 79 | 0.000 |
Why?
|
DNA Restriction Enzymes | 1 | 1989 | 122 | 0.000 |
Why?
|
Liver Neoplasms | 1 | 2000 | 1411 | 0.000 |
Why?
|
DNA Probes | 1 | 1989 | 125 | 0.000 |
Why?
|
Hormones | 1 | 1989 | 195 | 0.000 |
Why?
|
Chromatography, Affinity | 1 | 1988 | 71 | 0.000 |
Why?
|
Kinetics | 1 | 1990 | 1355 | 0.000 |
Why?
|
DNA Replication | 1 | 1989 | 363 | 0.000 |
Why?
|
Leukocytes | 1 | 1989 | 225 | 0.000 |
Why?
|
Rabbits | 1 | 1988 | 736 | 0.000 |
Why?
|
Risk Factors | 1 | 1991 | 11100 | 0.000 |
Why?
|